662 related articles for article (PubMed ID: 20138935)
41. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs.
van der Merwe SM; Verhoef JC; Verheijden JH; Kotzé AF; Junginger HE
Eur J Pharm Biopharm; 2004 Sep; 58(2):225-35. PubMed ID: 15296951
[TBL] [Abstract][Full Text] [Related]
42. Sodium caprate-induced increases in intestinal permeability and epithelial damage are prevented by misoprostol.
Brayden DJ; Maher S; Bahar B; Walsh E
Eur J Pharm Biopharm; 2015 Aug; 94():194-206. PubMed ID: 26026287
[TBL] [Abstract][Full Text] [Related]
43. 5β-Cholanic Acid/Glycol Chitosan Self-Assembled Nanoparticles (5β-CHA/GC-NPs) for Enhancing the Absorption of FDs and Insulin by Rat Intestinal Membranes.
Yan C; Gu J; Lv Y; Shi W; Huang Z; Liao Y
AAPS PharmSciTech; 2019 Jan; 20(1):30. PubMed ID: 30603934
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers.
Petersen SB; Nolan G; Maher S; Rahbek UL; Guldbrandt M; Brayden DJ
Eur J Pharm Sci; 2012 Nov; 47(4):701-12. PubMed ID: 22952065
[TBL] [Abstract][Full Text] [Related]
45. Preactivated thiomers: permeation enhancing properties.
Wang X; Iqbal J; Rahmat D; Bernkop-Schnürch A
Int J Pharm; 2012 Nov; 438(1-2):217-24. PubMed ID: 22960503
[TBL] [Abstract][Full Text] [Related]
46. Thiolated chitosans: influence of various sulfhydryl ligands on permeation-enhancing and P-gp inhibitory properties.
Sakloetsakun D; Iqbal J; Millotti G; Vetter A; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2011 Jun; 37(6):648-55. PubMed ID: 21561400
[TBL] [Abstract][Full Text] [Related]
47. The effect of hypergravity in intestinal permeability of nanoformulations and molecules.
Azevedo C; Macedo MH; Almeida A; Pinto S; van Loon JJWA; Sarmento B
Eur J Pharm Biopharm; 2021 Jun; 163():38-48. PubMed ID: 33785416
[TBL] [Abstract][Full Text] [Related]
48. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery.
Makhlof A; Tozuka Y; Takeuchi H
Eur J Pharm Sci; 2011 Apr; 42(5):445-51. PubMed ID: 21182939
[TBL] [Abstract][Full Text] [Related]
49. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs.
Takeuchi H; Matsui Y; Sugihara H; Yamamoto H; Kawashima Y
Int J Pharm; 2005 Oct; 303(1-2):160-70. PubMed ID: 16125348
[TBL] [Abstract][Full Text] [Related]
50. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats.
Lin Y; Fujimori T; Kawaguchi N; Tsujimoto Y; Nishimi M; Dong Z; Katsumi H; Sakane T; Yamamoto A
J Control Release; 2011 Jan; 149(1):21-8. PubMed ID: 20184931
[TBL] [Abstract][Full Text] [Related]
51. In vivo brain microdialysis to evaluate FITC-dextran encapsulated immunopegylated nanoparticles.
Bommana MM; Kirthivasan B; Squillante E
Drug Deliv; 2012 Aug; 19(6):298-306. PubMed ID: 22928708
[TBL] [Abstract][Full Text] [Related]
52. Delivery of berberine using chitosan/fucoidan-taurine conjugate nanoparticles for treatment of defective intestinal epithelial tight junction barrier.
Wu SJ; Don TM; Lin CW; Mi FL
Mar Drugs; 2014 Nov; 12(11):5677-97. PubMed ID: 25421323
[TBL] [Abstract][Full Text] [Related]
53. Efficacious intestinal permeation enhancement induced by the sodium salt of 10-undecylenic acid, a medium chain fatty acid derivative.
Brayden DJ; Walsh E
AAPS J; 2014 Sep; 16(5):1064-76. PubMed ID: 24961919
[TBL] [Abstract][Full Text] [Related]
54. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.
Garcia-Fuentes M; Prego C; Torres D; Alonso MJ
Eur J Pharm Sci; 2005 May; 25(1):133-43. PubMed ID: 15854809
[TBL] [Abstract][Full Text] [Related]
55. An oral oligonucleotide delivery system based on a thiolated polymer: Development and in vitro evaluation.
Martien R; Hoyer H; Perera G; Schnürch AB
Eur J Pharm Biopharm; 2011 Aug; 78(3):355-60. PubMed ID: 21295141
[TBL] [Abstract][Full Text] [Related]
56. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer.
Sadighi A; Ostad SN; Rezayat SM; Foroutan M; Faramarzi MA; Dorkoosh FA
Int J Pharm; 2012 Jan; 422(1-2):479-88. PubMed ID: 22101294
[TBL] [Abstract][Full Text] [Related]
57. Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles.
Liu L; Yang H; Lou Y; Wu JY; Miao J; Lu XY; Gao JQ
Int J Pharm; 2019 Feb; 557():170-177. PubMed ID: 30597264
[TBL] [Abstract][Full Text] [Related]
58. Poly(acrylic acid)-cysteine for oral vitamin B12 delivery.
Sarti F; Iqbal J; Müller C; Shahnaz G; Rahmat D; Bernkop-Schnürch A
Anal Biochem; 2012 Jan; 420(1):13-9. PubMed ID: 21964499
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers.
Quan YS; Hattori K; Lundborg E; Fujita T; Murakami M; Muranishi S; Yamamoto A
Biol Pharm Bull; 1998 Jun; 21(6):615-20. PubMed ID: 9657048
[TBL] [Abstract][Full Text] [Related]
60. Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles.
Joshi G; Kumar A; Sawant K
Drug Deliv; 2016 Nov; 23(9):3492-3504. PubMed ID: 27297453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
